Finfeed Archived May 12, 2020
PharmAust (ASX: PAA) has released promising data in relation to its monepantel canine trial, investigating the anti-cancer effects of monepantel tablets in dogs.
Get expert stock analysis direct in your inbox
Join OurMailing List
